IL17A and psoriasis: Considering the remarkable resemblance of the pathogeneses in psoriasis and CVDs, in this study, non-targeted metabolomics based on a high-throughput ultra-performance liquid chromatography mass spectrometry (UHPLC-MS) platform was used to clarify the metabolic alterations in IL-17A mAb-treated psoriasis patients in order to provide insight into the potential convergent mechanism in psoriasis and CVDs.